Skip to Content
Merck
CN

Key Documents

View All Documentation

PHR1624

Cisplatin

Pharmaceutical Secondary Standard; Certified Reference Material

Synonym(s):

cis-Diammineplatinum(II) dichloride, cis-Dichlorodiammine platinum(II), cis-Platinum(II) diammine dichloride, Cisplatin

Sign In to View Organizational & Contract Pricing.

Select a Size

Change View

About This Item

Linear Formula:
Pt(NH3)2Cl2
CAS Number:
15663-27-1
Molecular Weight:
300.05
NACRES:
NA.24
PubChem Substance ID:
329823516
UNSPSC Code:
41116107
EC Number:
239-733-8
MDL number:
MFCD00011623
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Quality Level

300

grade

certified reference material, pharmaceutical secondary standard

agency

traceable to Ph. Eur. C2210000, traceable to USP 1134357

API family

cisplatin

CofA

current certificate can be downloaded

packaging

pkg of 200 mg

technique(s)

HPLC: suitable, gas chromatography (GC): suitable

mp

270 °C (lit.)

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-30°C

SMILES string

N.N.Cl[Pt]Cl

InChI

1S/2ClH.2H3N.Pt/h2*1H;2*1H3;/q;;;;+2/p-2

InChI key

LXZZYRPGZAFOLE-UHFFFAOYSA-L

General description

Pharmaceutical secondary standards for application in quality control, provide pharma laboratories and manufacturers with a convenient and cost-effective alternative to the preparation of in-house working standards.
Cisplatin is an antineoplastic drug used for the treatment of cancer patients with a variety of different malignancies.

Application

Cisplatin may be used as an analytical reference standard for the determination of the analyte in plasma, cancer cell, and tumor samples by high-performance liquid chromatographic assay.
These Secondary Standards are qualified as Certified Reference Materials. These are suitable for use in several analytical applications including but not limited to pharma release testing, pharma method development for qualitative and quantitative analyses, food and beverage quality control testing, and other calibration requirements.

Biochem/physiol Actions

Potent platinum-based antineoplastic agent. Forms cytotoxic adducts with the DNA dinucleotide d(pGpG), inducing intrastrand cross-links.

Analysis Note

These secondary standards offer multi-traceability to the USP and EP primary standards, where they are available.

Other Notes

This Certified Reference Material (CRM) is produced and certified in accordance with ISO 17034 and ISO/IEC 17025. All information regarding the use of this CRM can be found on the certificate of analysis.
To see an example of a Certificate of Analysis for this material enter LRAB7778 in the slot below. This is an example certificate only and may not be the lot that you receive.

Still not finding the right product?

Explore all of our products under Cisplatin

pictograms

Skull and crossbonesHealth hazard
GHS06,GHS08

signalword

Danger

target_organs

Respiratory system

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Hazard Classifications

Acute Tox. 2 Oral - Carc. 1B - Eye Irrit. 2 - Muta. 1B - Repr. 1B - Resp. Sens. 1 - Skin Irrit. 2 - Skin Sens. 1 - STOT SE 3

Storage Class

6.1B - Non-combustible acute toxic Cat. 1 and 2 / very toxic hazardous materials

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Sample handling for determination of free platinum in blood after cisplatin exposure.
Johnsson A, et al.
Cancer Chemotherapy and Pharmacology, 41(3), 248-251 (1997)
A high-performance liquid chromatographic assay for determination of cisplatin in plasma, cancer cell, and tumor samples.
Lopez-Flores A, et al.
Journal of Pharmacological and Toxicological Methods, 52(3), 366-372 (2005)
Sonja Ludwig et al.
Cancer immunology, immunotherapy : CII, 68(7), 1133-1141 (2019-05-30)
Advanced oral squamous cell carcinomas (OSCC) have limited therapeutic options. Although immune therapies are emerging as a potentially effective alternative or adjunct to chemotherapies, the therapeutic efficacy of combination immune chemotherapies has yet to be determined. Using a 4-nitroquinolone-N-oxide (4NQO)
View All Related Papers

Global Trade Item Number

SKUGTIN
PHR1624-200MG04061835238088